4D Molecular TherapeuticsFDMT +4.34%55 PB Ratio is 1.56 as of Jun. 30, 2026, which is 2% above its 10-year median of 1.53. GuruFocus rates FDMT with a GF Score™ of 55/100 and a GF Value™ of $214.49 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,229 Biotechnology companies, 4D Molecular Therapeutics ranks better than 72.01% on this metric.
4D Molecular Therapeutics Inc stock PB Ratio (=1.49) is close to 1-year high of 1.49.
The historical rank and industry rank for 4D Molecular Therapeutics's PB Ratio or its related term are showing as below:
FDMT'
s PB Ratio Range Over the Past 10 Years
Min: 0.24 Med: 1.53 Max: 14.58
Current: 1.56
During the past 9 years, 4D Molecular Therapeutics's highest PB Ratio was 14.58. The lowest was 0.24. And the median was 1.53.
FDMT's PB Ratio is ranked better than 72.01% of 1229
companies
in the Biotechnology industry
Industry Median: 2.86
vs FDMT: 1.56
During the past 12 months, 4D Molecular Therapeutics's average Book Value Per Share Growth Rate was -14.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 7.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -0.30% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of 4D Molecular Therapeutics was 7.40% per year. The lowest was -9.40% per year. And the median was 4.00% per year.
Back to Basics: PB Ratio
4D Molecular Therapeutics (NAS:FDMT) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
4D Molecular Therapeutics PB Ratio Related Terms
4D Molecular Therapeutics PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, 4D Molecular Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4D Molecular Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where 4D Molecular Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
4D Molecular Therapeutics (FDMT) has a PB Ratio of 1.56 as of Jun. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on 4D Molecular Therapeutics and its competitors. This is near median its historical median of 1.53. Over the past decade, 4D Molecular Therapeutics' PB Ratio has ranged from 0.24 to 14.58. According to the industry distribution chart, 4D Molecular Therapeutics ranks #344 out of 1229 companies in the Biotechnology industry, placing it in the top 28%.
Is 4D Molecular Therapeutics' PB Ratio too high?
4D Molecular Therapeutics' current PB Ratio of 1.56 is near median its 10-year median of 1.53. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 14.58. The Biotechnology industry median PB Ratio is 2.86. 4D Molecular Therapeutics' value of 1.56 is 45.5% below this industry median. Based on the distribution chart, 4D Molecular Therapeutics ranks #344 out of 1229 companies in the Biotechnology industry, which is above the industry midpoint. Overall, 4D Molecular Therapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4D Molecular Therapeutics' PB Ratio compare to TECX and ACHV?
According to the Biotechnology industry distribution chart, 4D Molecular Therapeutics ranks #344 out of 1229 companies for PB Ratio. This puts 4D Molecular Therapeutics in the upper half of its industry. The industry median PB Ratio is 2.86. 4D Molecular Therapeutics' value of 1.56 is 45.5% below this benchmark. Historically, 4D Molecular Therapeutics' own PB Ratio has ranged from 0.24 to 14.58 over the past decade. While the company's 10-year median is 1.53 vs. the industry median of 2.86, 4D Molecular Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.86, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 4D Molecular Therapeutics's current PB Ratio of 1.56 is 45.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on 4D Molecular Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4D Molecular Therapeutics's current PB Ratio is 1.56, which is near median its own 10-year median of 1.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4D Molecular Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, 4D Molecular Therapeutics (FDMT) is currently considered Possible Value Trap. The stock's GF Value™ is $214.49, compared to a current price of $13.46 — trading 93.7% below its estimated fair value. The current PB Ratio is 1.56, which is near median its 10-year median of 1.53 and 45.5% below the Biotechnology industry median of 2.86. 4D Molecular Therapeutics' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For 4D Molecular Therapeutics (FDMT), the current PB Ratio is 1.56 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 4D Molecular Therapeutics (FDMT) Overvalued in 2026?
Based on GuruFocus' analysis, 4D Molecular Therapeutics stock appears to be undervalued.
The current stock price of $13.46 is trading 93.7% below its estimated GF Value™ of $214.49.
GuruFocus considers 4D Molecular Therapeutics to be Possible Value Trap.
Key valuation signals for FDMT:
PB Ratio: 1.56 (near median its 10-year median of 1.53)
GF Value™: $214.49 vs. price of $13.46 (93.7% below fair value)
Industry Position: 45.5% below the Biotechnology median (#344 of 1229)
No single metric tells the full story. See the FDMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
55GF Score
Get the complete analysis for FDMT
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FDMT has been successfully added to your 
